Advanced search
Publication Cover
Leukemia & Lymphoma Volume 64, 2023 - Issue 14
Submit an article Journal homepage
174
Views
0
CrossRef citations to date
0
Altmetric
Letters to the Editor

Preclinical activity of a novel multi-axis inhibitor in aggressive and indolent B-cell malignancies

Audrey L. Smitha Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USAView further author information
,
Dhananjaya Palb College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA;c Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, CA, USAView further author information
,
Rolando Martinez-Ricoa Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USAView further author information
,
Alexandria P. Eikena Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USAView further author information
,
Donald L. Durdenb College of Pharmacy, University of Nebraska Medical Center, Omaha, NE, USA;c Division of Hematology and Oncology, Department of Pediatrics, Moores Cancer Center, University of California San Diego, CA, USAView further author information
,
Tatiana G. Kutateladzed Department of Pharmacology, University of Colorado School of Medicine, Aurora, CO, USAView further author information
&
Dalia El-Gamala Eppley Institute for Research in Cancer and Allied Diseases, University of Nebraska Medical Center, Omaha, NE, USA;e Fred and Pamela Buffett Cancer Center, University of Nebraska Medical Center, Omaha, NE, USACorrespondence[email protected]
View further author information
 show all
Pages 2333-2337 | Received 07 Mar 2023, Accepted 30 Aug 2023, Published online: 14 Sep 2023

References

  • Puente XS, Jares P, Campo E. Chronic lymphocytic leukemia and mantle cell lymphoma: crossroads of genetic and microenvironment interactions. Blood. 2018;131(21):2283–2296. doi:10.1182/blood-2017-10-764373
  • Hallek M, Al-Sawaf O. Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures. Am J Hematol. 2021;96(12):1679–1705. doi:10.1002/ajh.26367
  • Jain P, Wang ML. Mantle cell lymphoma in 2022-A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments. Am J Hematol. 2022;97(5):638–656. doi:10.1002/ajh.26523
  • Pal D, Vann KR, Joshi S, et al. The BTK/PI3K/BRD4 axis inhibitor SRX3262 overcomes ibrutinib resistance in mantle cell lymphoma. iScience. 2021;24(9):102931. PubMed PMID: 34557659; PubMed Central PMCID: PMCPMC8445847. doi:10.1016/j.isci.2021.102931
  • Smith AL, Eiken AP, Skupa SA, et al. A novel Triple-Action inhibitor targeting B-Cell receptor signaling and BRD4 demonstrates preclinical activity in chronic lymphocytic leukemia. Int J Mol Sci. 2022;23(12):6712. PubMed PMID: 35743155; PubMed Central PMCID: PMCPMC9224275. doi:10.3390/ijms23126712
  • Vann KR, Pal D, Smith AL, et al. Combinatorial inhibition of BTK, PI3K-AKT and BRD4-MYC as a strategy for treatment of mantle cell lymphoma. Mol Biomed. 2022;3(1):2. PubMed PMID: 35031886; PubMed Central PMCID: PMCPMC8760370. doi:10.1186/s43556-021-00066-9
  • Andrews FH, Singh AR, Joshi S, et al. Dual-activity PI3K-BRD4 inhibitor for the orthogonal inhibition of MYC to block tumor growth and metastasis. Proc Natl Acad Sci U S A. 2017;114(7):E1072–E1080. PubMed PMID: 28137841; PubMed Central PMCID: PMCPMC5320964. doi:10.1073/pnas.1613091114
  • Vann KR, Pal D, Morales GA, et al. Design of thienopyranone-based BET inhibitors that bind multiple synthetic lethality targets. Sci Rep. 2020;10(1):12027. PubMed PMID: 32694708; PubMed Central PMCID: PMCPMC7374098 Inc. doi:10.1038/s41598-020-68964-6
  • Morales G, Garlich JR, Durden DL. Single molecule compounds providing multi-target inhibition of btk and other proteins and methods of use thereof. Patent number WO2020023340A1. 2020.
  • Sun B, Shah B, Fiskus W, et al. Synergistic activity of BET protein antagonist-based combinations in mantle cell lymphoma cells sensitive or resistant to ibrutinib. Blood. 2015;126(13):1565–1574. PubMed PMID: 26254443; PubMed Central PMCID: PMCPMC4582333. doi:10.1182/blood-2015-04-639542
  • Derenzini E, Mondello P, Erazo T, et al. BET inhibition-induced GSK3beta feedback enhances lymphoma vulnerability to PI3K inhibitors. Cell Rep. 2018;24(8):2155–2166. PubMed PMID: 30134175; PubMed Central PMCID: PMCPMC7456333. doi:10.1016/j.celrep.2018.07.055
  • Delmore JE, Issa GC, Lemieux ME, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146(6):904–917. PubMed PMID: 21889194; PubMed Central PMCID: PMCPMC3187920. doi:10.1016/j.cell.2011.08.017
  • Ozer HG, El-Gamal D, Powell B, et al. BRD4 profiling identifies critical chronic lymphocytic leukemia oncogenic circuits and reveals sensitivity to PLX51107, a novel structurally distinct BET inhibitor. Cancer Discov. 2018;8(4):458–477. PubMed PMID: 29386193; PubMed Central PMCID: PMCPMC5882533. doi:10.1158/2159-8290.CD-17-0902
  • Boddu P, Ferrajoli A. Prognostic factors in the era of targeted therapies in CLL. Curr Hematol Malig Rep. 2018;13(2):78–90. doi:10.1007/s11899-018-0439-9
  • Decker T, Schneller F, Sparwasser T, et al. Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells. Blood. 2000;95(3):999–1006. PubMed PMID

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.